BPC-157 vs TB-500: What the Research Actually Compares

BPC-157 is a 15-amino-acid peptide derived from a gastric protein, studied mainly in tendon, ligament and gut-lining models. TB-500 is a 7-residue synthetic fragment of thymosin β4, an actin-binding protein, studied for cell migration and angiogenesis. They share a research category, not a mechanism. Both are supplied as 10 mg lyophilized vials with batch COAs, and as a pre-blended pen.

What each peptide is

BPC-157 — Body Protection Compound-157 — is a synthetic pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, 1419.5 g/mol). Its sequence comes from a protective protein isolated from human gastric juice, and the originating research group has described its notable stability in acid [1].

TB-500 is a synthetic seven-residue fragment (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln) of thymosin β4, a 43-amino-acid protein present in nearly all mammalian cells whose primary job is binding G-actin — the building block of the cytoskeleton. The fragment carries the actin-binding motif and is used in research as a smaller stand-in for that active site [2].

So the first difference is origin: one is gut-derived, the other is a piece of a ubiquitous cytoskeletal regulator.

Mechanisms studied

The BPC-157 literature — the great majority of it from one Croatian research group — frames the compound's studied activity around angiogenesis and the nitric-oxide system [3], with tendon and ligament models as the most-cited application: a 2011 rat study reported effects on tendon outgrowth, fibroblast survival and migration [4].

The thymosin β4 literature is broader and older. Its actin-sequestering role is the mechanistic foundation [2]; from that follow the cell-migration, angiogenesis and tissue-repair models in which it and its fragments are studied, including cardiac repair [5] and inflammation-through-autophagy work [6].

Research models compared

• Tendon and ligament: BPC-157 dominates this literature [4][7].
• Cell migration and wound-closure assays: thymosin β4 and fragments dominate [2][8].
• Gastrointestinal models: BPC-157, by origin [1].
• Cardiac models: thymosin β4 [5].
• Angiogenesis: both appear, through different studied pathways [3][2].

Can they be evaluated together?

They often are, precisely because they are different: a laboratory studying a recovery model may want a gastric-derived peptide and an actin-pathway fragment in the same series. There is no published evidence of chemical incompatibility — they are co-formulated in the BPC-157 & TB-500 research pen, where the COA reports each component separately. Whether to combine them is a protocol decision for the researcher, not something APX Labs advises on.

Specifications side by side

• Length: BPC-157 15 residues · TB-500 7 residues
• Origin: gastric juice protein fragment · thymosin β4 fragment
• Molecular weight: 1419.5 g/mol · fragment mass as reported on the COA (the parent thymosin β4 is ~4,963 g/mol)
• Format: 10 mg lyophilized vial each; blend pen 40 mg
• Testing: independent HPLC purity + MS identity, batch COA
• Price: BPC-157 $50 · TB-500 $61 · blend $299

Everything above describes laboratory and animal research. APX Labs products are for research use only, are not for human or veterinary use, and nothing here is a claim of effect.

Frequently asked